Dashboard
Low ability to service debt as the company has a high Debt to EBITDA ratio of 7.65 times
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 7.65 times
- The company has been able to generate a Return on Equity (avg) of 6.13% signifying low profitability per unit of shareholders funds
Stock is technically in a Mildly Bearish range
Reducing Promoter Confidence
Stock DNA
Pharmaceuticals & Biotechnology
INR 10,453 Cr (Small Cap)
39.00
40
0.00%
0.03
8.22%
3.29
Total Returns (Price + Dividend) 
Latest dividend: 0.5 per share ex-dividend date: Sep-08-2021
Risk Adjusted Returns v/s 
Returns Beta
News

Viyash Scientific Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals
Viyash Scientific Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 19 Nov 2026. This change reflects a complex interplay of factors across financial performance, valuation metrics, technical indicators, and overall quality assessments, signalling caution for investors despite some positive operational results.
Read More
Viyash Scientific Ltd Faces Technical Downgrade Amid Mixed Momentum Signals
Viyash Scientific Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, RSI, and moving averages, signal a cautious outlook for investors as the stock navigates mixed signals across weekly and monthly timeframes.
Read More
Viyash Scientific Ltd Forms Death Cross, Signalling Potential Bearish Trend
Viyash Scientific Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
19-Nov-2026 | Source : BSEESOP Allotment
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
17-Nov-2026 | Source : BSEEarnings Call Transcript is attached.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14-Nov-2026 | Source : BSEPlease find attached disclosure regarding outcome of the Earnings Call
Corporate Actions 
No Upcoming Board Meetings
Viyash Scientific Ltd has declared 25% dividend, ex-date: 08 Sep 21
Viyash Scientific Ltd has announced 2:10 stock split, ex-date: 25 Feb 16
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 9 Schemes (7.13%)
Held by 32 FIIs (2.6%)
Ca Hull Investments (31.17%)
Haribabu Bodepudi (2.77%)
26.74%
Quarterly Results Snapshot (Consolidated) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 16.19% vs 130.65% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 38.72% vs 2,003.83% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 14.04% vs 11.73% in Sep 2024
Growth in half year ended Sep 2025 is 218.53% vs 121.10% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 12.46% vs 51.99% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 25.61% vs 253.69% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 13.75% vs 119.52% in Mar 2025
YoY Growth in year ended Mar 2026 is 663.48% vs 164.72% in Mar 2025